Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Comparison of Talquetamab vs Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
2022-001442-38Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Talquetamab with Belantamab Mafodotin (2 arms). Primary endpoints: Overall response rate and Progression-free survival. Started Aug 2022; status: active.
02
Drugs
talquetamabbelantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-001442-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001442-38.